A framework for applying unfamiliar trial designs in studies of rare diseases
- 1 October 2011
- journal article
- review article
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 64 (10) , 1085-1094
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerationsJournal of Clinical Epidemiology, 2010
- Adaptive Designs for Randomized Trials in Public HealthAnnual Review of Public Health, 2009
- Shifting Our Thinking About Uncommon Disease Trials: The Case of Methotrexate in SclerodermaThe Journal of Rheumatology, 2009
- Adaptive design methods in clinical trials – a reviewOrphanet Journal of Rare Diseases, 2008
- Power and sample size simulations for Randomized Play-the-Winner rulesContemporary Clinical Trials, 2007
- Adopting Orphan Drugs — Two Dozen Years of Treating Rare DiseasesNew England Journal of Medicine, 2006
- Strategy for randomised clinical trials in rare cancersBMJ, 2003
- The importance of pilot studiesNursing Standard, 2002
- A randomized, controlled trial of methotrexate versus placebo in early diffuse sclerodermaArthritis & Rheumatism, 2001
- Internal pilot studies for estimating sample sizeStatistics in Medicine, 1994